Takanori Teshima

87PUBLICATIONS
319CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)HaematologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (87)

|Jul 13, 2026
PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation.

|Jun 25, 2026
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

|Apr 27, 2026
Differences in Perspectives and Policies Regarding End-of-Life Care Between Hematologists and Gastroenterologists.

|Nov 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

|Nov 10, 2025
Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama

|Jul 03, 2025
Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.

Minoru Kanaya, Masahiro Onozawa, Toshihiro Matsukawa

Pageof 15

Frequent Collaborators

14 joint publications

Daigo Hashimoto

10 joint publications

Masahiro Onozawa

9 joint publications

Takahide Ara

7 joint publications

Takeshi Kondo